Cardiology

Episodes 113-128 of 191

What the SODIUM-HF Trial Means for Heart Failure Patients
What the SODIUM-HF Trial Means for Heart Failure Patients
Heart Matters
What the SODIUM-HF Trial Means for Heart Failure Patients
- Javed Butler
- Justin Ezekowitz, MD, MBBCh, MSc
Novel Form of CV Research with Dietary Education in the Grocery Store
Novel Form of CV Research with Dietary Education in the Grocery Store
ACC Action Center
Novel Form of CV Research with Dietary Education in the Grocery Store
Treatment of Chronic Hypertension Reduces Adverse Pregnancy Outcomes
Treatment of Chronic Hypertension Reduces Adverse Pregnancy Outcomes
ACC Action Center
Treatment of Chronic Hypertension Reduces Adverse Pregnancy Outcomes
Impact of New First-in-Class Medical Therapy in Obstructive HCM
Impact of New First-in-Class Medical Therapy in Obstructive HCM
ACC Action Center
Impact of New First-in-Class Medical Therapy in Obstructive HCM
Beginning of an Era: Treatment of Elevated Lp(a)
Beginning of an Era: Treatment of Elevated Lp(a)
ACC Action Center
Beginning of an Era: Treatment of Elevated Lp(a)
Cardiac Myosin Inhibitor Reduces Need for Septal Reduction Therapy in Obstructive HCM
Cardiac Myosin Inhibitor Reduces Need for Septal Reduction Therapy in Obstructive HCM
ACC Action Center
Cardiac Myosin Inhibitor Reduces Need for Septal Reduction Therapy in Obstructive HCM
Reductions in LVOT Gradients, NYHA Class, & NT-proBNP with Cardiac Myosin Inhibitor in HCM
Reductions in LVOT Gradients, NYHA Class, & NT-proBNP with Cardiac Myosin Inhibitor in HCM
ACC Action Center
Reductions in LVOT Gradients, NYHA Class, & NT-proBNP with Cardiac Myosin Inhibitor in HCM
Cardiac Myosin Inhibitor Sustainably Reduces LVOT Gradient in HCM
Cardiac Myosin Inhibitor Sustainably Reduces LVOT Gradient in HCM
ACC Action Center
Cardiac Myosin Inhibitor Sustainably Reduces LVOT Gradient in HCM
A First Clinical Trial Testing the Use of an H2S Donor After Heart Attack
A First Clinical Trial Testing the Use of an H2S Donor After Heart Attack
ACC Action Center
A First Clinical Trial Testing the Use of an H2S Donor After Heart Attack
Updates in the New AHA/ACC/HFSA Heart Failure Guideline
Updates in the New AHA/ACC/HFSA Heart Failure Guideline
ACC Action Center
Updates in the New AHA/ACC/HFSA Heart Failure Guideline
PCSK9i Reduces Plaque Burden in Coronary Arteries
PCSK9i Reduces Plaque Burden in Coronary Arteries
ACC Action Center
PCSK9i Reduces Plaque Burden in Coronary Arteries
Study with ASO Targeting ANGPTL3 mRNA Highlights Importance of Rigorous Evaluation of New Therapies
Study with ASO Targeting ANGPTL3 mRNA Highlights Importance of Rigorous Evaluation of New Therapies
ACC Action Center
Study with ASO Targeting ANGPTL3 mRNA Highlights Importance of Rigorous Evaluation of New Therapies
Reduction of Bleeding with Tranexamic Acid After Noncardiac Surgery
Reduction of Bleeding with Tranexamic Acid After Noncardiac Surgery
ACC Action Center
Reduction of Bleeding with Tranexamic Acid After Noncardiac Surgery
Breaking Down the Criteria for Iron Deficiency in Heart Failure
Breaking Down the Criteria for Iron Deficiency in Heart Failure
Heart Matters
Breaking Down the Criteria for Iron Deficiency in Heart Failure
- Javed Butler
- John Cleland
- Fraser Graham, MD
Challenging the Theory That Light Alcohol Consumption Benefits Heart Health
Challenging the Theory That Light Alcohol Consumption Benefits Heart Health
Heart Matters
Challenging the Theory That Light Alcohol Consumption Benefits Heart Health
Dissecting Disparities in Cardiogenic Shock Treatment & Survival
Dissecting Disparities in Cardiogenic Shock Treatment & Survival
Heart Matters
Dissecting Disparities in Cardiogenic Shock Treatment & Survival

8/10

Episodes 113-128 of 191

Title

Share on ReachMD

Welcome to Global Cardiology Academy

Welcome to Global
Cardiology Academy